Side-by-side comparison of AI visibility scores, market position, and capabilities
Lake Forest IL industrial pumps and specialty equipment (NYSE: IEX) ~$3.7B FY2024 revenue (-6% destocking); Viking Pump, fire suppression, precision fluidics for diagnostics, Muon acquisition competing with Roper Technologies.
IDEX Corporation is a Lake Forest, Illinois-based industrial pumps and specialty equipment company — publicly traded on the New York Stock Exchange (NYSE: IEX) as an S&P 500 Industrials component — manufacturing specialized pumps, flow measurement equipment, fire suppression systems, and analytical instrumentation through three operating segments: Fluid & Metering Technologies (precision industrial pumps for food/beverage, chemical, and industrial applications), Health & Science Technologies (precision fluid handling for medical devices, analytical instruments, and life science research equipment), and Fire & Safety/Diversified Products (suppression equipment, rescue tools, and band-it cable products) through approximately 9,400 employees across 30+ brands in 20+ countries. In fiscal year 2024, IDEX Corporation reported revenues of approximately $3.7 billion (-6% decline from 2023 peak) and adjusted EBITDA of approximately $1.0 billion, as the industrial equipment market experienced broad destocking as customers who over-ordered during the 2022 supply chain crisis worked through accumulated inventory before placing new orders. CEO Eric Ashleman has maintained IDEX's strategy of organic and acquisition-driven portfolio evolution in niche markets where deep application engineering knowledge creates sustained competitive differentiation: IDEX's 2023 acquisition of Iridex ($52 million — laser therapy devices for glaucoma and retinal diseases) and Muon Group (a $1.1 billion acquisition of materials processing and spectroscopy instrumentation) expands IDEX's presence in precision medical device and analytical science applications. IDEX's operational philosophy (the IDEX Business System — continuous improvement across lean manufacturing, customer intimacy, and talent development) mirrors Danaher's DBS approach of applying systematic process improvement across diverse industrial businesses to extract organic margin expansion beyond acquisition contribution.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.